Hepatitis B virus (HBV) covalently closed circular (ccc) DNA plays a central role in the establishment of viral infection and persistence, and is the basis for viral rebound after the cessation of therapy, as well as the elusiveness of a cure even after extended treatment with current approved medications. HBV cccDNA is established upon initial infection through conversion of the partially double stranded relaxed circular (rc) DNA virl genome, presumably through employment of the host cell's DNA repair mechanisms in the nucleus. The cccDNA episome levels are maintained through a replication pathway that involves retrotranscription of a cccDNA transcript, termed pregenomic RNA, into progeny rcDNA genomes, some of which are returned to the nucleus for conversion into cccDNA. The conversion of rcDNA into cccDNA requires the removal of a covalently-linked copy of the polymerase from the 5' end of one of the DNA strands, and this deproteinization step generates a DNA intermediate, the deproteinized rcDNA (DP-rcDNA), as precursor for cccDNA formation. In addition, our previous work suggested that the rcDNA deproteinization is a trigger signal for transportation of HBV nucleocapsid containing mature viral DNA into nucleus, where the rcDNA to cccDNA conversion takes place. However, there are many details yet to be elucidated in the understanding of cccDNA formation and metabolism. In this research application, by making use of a battery of molecular biology, biochemistry, and proteomics technologies specially designed for cccDNA study, we propose to further characterize the terminal structure and the state of existence of both cytoplasmic and nuclear DP-rcDNA, elucidate the molecular mechanisms of rcDNA deproteinization, and systematically identify host DNA repair genes involved in rcDNA to cccDNA conversion. Our ultimate goal is to illustrate a coherent picture of the molecular mechanisms/pathway for HBV cccDNA formation. The accomplishment of this project will fill a significant knowledge gap in HBV molecular biology, and potentially provide new antiviral targets for development of novel therapeutics for hepatitis B.

Public Health Relevance

Chronic hepatitis B remains a significant public health burden affecting approximately 300 million individuals worldwide, and those patients have a high risk of occurrence of cirrhosis and liver cancer. Chronic HBV infection is maintained by a persistent viral genome called cccDNA, which could not be eradicated by currently approved drugs. We propose in this application to elucidate the molecular mechanisms and pathway of cccDNA formation, which will discover new antiviral targets for future development of novel HBV therapeutics.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project (R01)
Project #
Application #
Study Section
Virology - A Study Section (VIRA)
Program Officer
Koshy, Rajen
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Indiana University-Purdue University at Indianapolis
Schools of Medicine
United States
Zip Code
Wei, Xia-Fei; Gan, Chun-Yang; Cui, Jing et al. (2018) Identification of Compounds Targeting Hepatitis B Virus Core Protein Dimerization through a Split Luciferase Complementation Assay. Antimicrob Agents Chemother 62:
Alter, Harvey; Block, Timothy; Brown, Nathaniel et al. (2018) A research agenda for curing chronic hepatitis B virus infection. Hepatology 67:1127-1131
Mitra, Bidisha; Thapa, Roshan J; Guo, Haitao et al. (2018) Host functions used by hepatitis B virus to complete its life cycle: Implications for developing host-targeting agents to treat chronic hepatitis B. Antiviral Res 158:185-198
Cai, Xiaodan; Zheng, Weihao; Pan, Shaokun et al. (2018) A virus-like particle of the hepatitis B virus preS antigen elicits robust neutralizing antibodies and T cell responses in mice. Antiviral Res 149:48-57
Liu, Shi; Zhou, Bin; Valdes, Juan D et al. (2018) Serum HBV RNA: a New Potential Biomarker for Chronic Hepatitis B Virus Infection. Hepatology :
Mani, Nagraj; Cole, Andrew G; Phelps, Janet R et al. (2018) Preclinical Profile of AB-423, an Inhibitor of Hepatitis B Virus Pregenomic RNA Encapsidation. Antimicrob Agents Chemother 62:
Liu, Yuanjie; Nie, Hui; Mao, Richeng et al. (2017) Interferon-inducible ribonuclease ISG20 inhibits hepatitis B virus replication through directly binding to the epsilon stem-loop structure of viral RNA. PLoS Pathog 13:e1006296
Hong, Xupeng; Kim, Elena S; Guo, Haitao (2017) Epigenetic regulation of hepatitis B virus covalently closed circular DNA: Implications for epigenetic therapy against chronic hepatitis B. Hepatology 66:2066-2077
Zhang, Yongmei; Mao, Richeng; Guo, Haitao et al. (2017) Detection of HBV cccDNA Methylation from Clinical Samples by Bisulfite Sequencing and Methylation-Specific PCR. Methods Mol Biol 1540:73-84
Pang, Jinke; Zhang, Geng; Lin, Yong et al. (2017) Transforming growth factor ?-activated kinase 1 transcriptionally suppresses hepatitis B virus replication. Sci Rep 7:39901

Showing the most recent 10 out of 16 publications